Topic:

Emerging Markets

Latest Headlines

Latest Headlines

In snit over supply, not prices, MSF urges South Africa to override AbbVie drug patent

Doctors Without Borders (MSF) often has a bone to pick with Big Pharma, especially when it comes to the industry's patents on expensive life-extending meds. As part of its latest tirade, the group is urging the South African government to override a patent for AbbVie's HIV drug, Aluvia, after shortages of the med cropped up in the country.

AstraZeneca opens plant in Russia

AstraZeneca has laid out a host of new manufacturing projects in recent months, including new biologics plants in Europe and the U.S. But while those projects are in the works, it has a new tablet plant in Russia that has just gone online.

Pharma's newest nemesis? Nestlé works at the intersection of food and drugs to attack illnesses

If Big Pharma didn't already have enough to worry about, with patent cliffs, drug price investigations and reluctant payers, it now will have to face the onslaught of a large, well-funded company trying to create hybrid pharma and food products company that would treat conditions from stomach disorders to Alzheimer's disease.

Teva beefs up in emerging markets with $2.3B Rimsa buyout

Last month, names like Sanofi, Pfizer, Abbott and Takeda were flying around as potential suitors for Mexico-based Representaciones e Investigaciones Medicas, aka Rimsa. But it's Teva that's emerged victorious in the field.

Abbott said to expand manufacturing, other operations in India

Abbott Laboratories wlll expand its manufacturing, as well as other operations, in India, though a dollar amount was not given by the pharmaceutical giant.

Merck KGaA counts on Latin America to power consumer-health future

Lately, Latin America has been leading the growth ranks for Merck KGaA's consumer health unit. And that's not set to change anytime soon, its leader says.

Manufacturers' association says pharma contract manufacturing in India growing at 20%

The Indian Drug Manufacturers' Association says the country's pharmaceutical contract manufacturing industry is growing at 20%.

Novartis brings heart, cancer meds to low-income countries for $1 per month

Novartis has stood by its commitment to emerging markets even in rocky times. And now, it's furthering that commitment with an access initiative for low-income countries.

ShangPharma plots a $60M splash for biologics R&D in China

Chinese contract drug developer ShangPharma is planning to invest $60 million to build a biologics research and manufacturing outpost near its home base in Shanghai.

Serum Institute sets out for dengue fast track

Asia's largest vaccinemaker just made a play that could affect the race for a vaccine protecting against dengue fever, a common affliction that has a big impact in the region.
'